The Health Insurance Review and Assessment Service said, “We will prepare a final plan within this year” to an inquiry on the progress made on the reevaluation of off-patent drugs through a comparison of overseas drug prices.

In particular, based on the established reevaluation standards, HIRA also expressed their intention to sequentially carry out reevaluations starting next year and reduce the prices of drugs listed at higher prices compared to overseas to secure the financial sustainability of Korea’s national health insurance.

Such will were found in the response submitted to answer People Power Party Rep. Young-Hee Choi’s written inquiry during the NA audit on the 25th.